Infrastructure for Oncology Treatment Selection (Precision Medicine)
AI system that recommends personalized cancer treatment protocols based on tumor genomics, patient characteristics, and treatment response patterns from similar patients.
Analysis based on CMC Framework: 730 capabilities, 560+ vendors, 7 industries.
Key Finding
Oncology Treatment Selection (Precision Medicine) requires CMC Level 4 Formality for successful deployment. The typical clinical operations & patient care organization in Healthcare faces gaps in 4 of 6 infrastructure dimensions. 1 dimension is structurally blocked.
Structural Coherence Requirements
The structural coherence levels needed to deploy this capability.
Requirements are analytical estimates based on infrastructure analysis. Actual needs may vary by vendor and implementation.
Why These Levels
The reasoning behind each dimension requirement.
Oncology treatment selection requires machine-executable formalization of NCCN guidelines, biomarker-driven treatment decision trees, and clinical trial eligibility criteria. The AI must apply: IF Tumor.EGFR.Mutation = Exon19Del AND Patient.Performance.Status <= 2 THEN Recommend.Osimertinib WITH Evidence.Level = 1A—not 'consider targeted therapy for actionable mutations.' FDA-approved biomarker-drug pairings, tumor mutation burden thresholds for immunotherapy, and clinical trial inclusion/exclusion criteria must be formalized as executable logic, not documented guidelines for oncologist reference.
Precision medicine treatment selection requires systematic capture of tumor genomic results (NGS panel findings), biomarker test results (PD-L1 IHC, MSI status), treatment response data, and toxicity assessments through defined oncology workflow templates. Molecular tumor board case templates ensure complete genomic data is structured for the AI. Without template-driven capture, critical genomic variables are buried in PDF pathology reports that the AI cannot reliably extract.
Precision oncology requires formal ontology defining Tumor.Genomic.Alteration entities (mutation, amplification, fusion, deletion) with their relationships to Gene, Drug, and Evidence nodes: BRCA1.Mutation → Olaparib WITH Evidence.Level = FDA_Approved AND Patient.Condition = Ovarian.Cancer. Clinical trial eligibility requires formal encoding of inclusion/exclusion criteria as queryable entities. Without formal ontology mapping genomic findings to therapeutic options, the AI cannot generate ranked treatment recommendations or identify trial matches.
Oncology treatment selection requires unified API access to: genomics lab systems (NGS results), EHR (complete medical history, current medications, organ function labs), clinical trial registries (ClinicalTrials.gov or institutional trial database), and formulary systems (drug availability, cost). These disparate data sources must be assembled into a unified patient-plus-tumor context for the AI to generate comprehensive treatment recommendations. Querying each system separately produces an incomplete picture that generates clinically unsafe recommendations.
Oncology treatment guidelines, FDA drug approvals, and clinical trial availability update frequently—new biomarker-drug approvals occur multiple times per year from FDA. NCCN guideline versions update quarterly. Event-triggered updates when new FDA approvals or major guideline revisions occur ensure the AI recommends currently approved agents. Open clinical trial databases require regular synchronization as trials open and close enrollment.
Oncology treatment selection requires API-based connections between EHR, genomics laboratory systems, clinical trial registry databases, formulary systems, and tumor board workflow platforms. Treatment recommendations must flow into the oncologist's clinical decision support interface and potentially the care plan documentation in the EHR. Multi-system API integration enables the complete precision medicine workflow—matching genomic findings to approved therapies and open trials simultaneously.
What Must Be In Place
Concrete structural preconditions — what must exist before this capability operates reliably.
Primary Structural Lever
How explicitly business rules and processes are documented
The structural lever that most constrains deployment of this capability.
How explicitly business rules and processes are documented
- Machine-readable oncology treatment selection criteria codifying biomarker thresholds, mutation classifications, and contraindication rules for each approved therapy with evidence grade references
Whether operational knowledge is systematically recorded
- Systematic capture of NGS panel results, biomarker values, and treatment response outcomes into structured oncology records with variant classifications mapped to standardized nomenclature
How data is organized into queryable, relational formats
- Formal oncology ontology mapping tumor types, genomic alterations, biomarkers, and treatment agents to standardized codes (HGNC, ClinVar, RxNorm) with actionability classifications
Whether systems expose data through programmatic interfaces
- Semantic API layer providing real-time access to patient tumor genomics, prior treatment history, current medication list, and clinical trial eligibility criteria
How frequently and reliably information is kept current
- Version-controlled oncology knowledge base with review cycles triggered by new FDA approvals, NCCN guideline updates, and emerging biomarker evidence
Whether systems share data bidirectionally
- Integration middleware connecting genomics laboratory systems, clinical trial matching databases, and oncology EHR to assemble patient-specific treatment context
Common Misdiagnosis
Oncology programs invest in genomic sequencing volume and AI matching algorithms while treatment criteria remain in narrative NCCN guideline PDFs — the system cannot map a variant report to an evidence-supported therapy because treatment selection rules have never been codified.
Recommended Sequence
Establish machine-readable treatment criteria and oncology ontology with variant-to-actionability mapping in parallel before integrating genomics data feeds — the matching algorithm requires both structured knowledge and standardized variant representation.
Gap from Clinical Operations & Patient Care Capacity Profile
How the typical clinical operations & patient care function compares to what this capability requires.
More in Clinical Operations & Patient Care
Frequently Asked Questions
What infrastructure does Oncology Treatment Selection (Precision Medicine) need?
Oncology Treatment Selection (Precision Medicine) requires the following CMC levels: Formality L4, Capture L3, Structure L4, Accessibility L4, Maintenance L3, Integration L3. These represent minimum organizational infrastructure for successful deployment.
Which industries are ready for Oncology Treatment Selection (Precision Medicine)?
The typical Healthcare clinical operations & patient care organization is blocked in 1 dimension: Accessibility.
Ready to Deploy Oncology Treatment Selection (Precision Medicine)?
Check what your infrastructure can support. Add to your path and build your roadmap.